gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HURAHealthcarePharmaceuticals

TuHURA Biosciences, Inc. Common Stock (HURA)

$2.18+8.46%
Close Oct 23, 2026 · split-adjusted
Oct 23, 2026$2.18▼ 2.24% in range
Oct 23, 2025Low $0.44 · High $3.15Oct 23, 2026
What changed · written from our data
As of Oct 23, 2026

TuHURA Biosciences closed at $2.18 on Oct 23, up 8.46%, 30.8% below its 52-week closing high. Volume of 1.0M shares was 3.71× its 20-day average (well above normal).

Split-adjusted performance: +3.8% over one month, -7.2% over six months, -3.1% over one year.

Short interest was 6.1M shares at the Sep 30 settlement, down 2.9% from the prior report (13.7% of float, 28.4 days to cover).

Market cap$138.9M63.7M shares
Revenue · quarter$0.00—
Diluted EPS$-0.14—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range0.44 – 3.15−30.8% from high
Volume1.0M3.71× 20-day avg
Volatility · 60d67.7%Annualised
Short % of float13.7%28.4 days to cover
Net cash-$4.2MCash $996.0K
Next earnings—Not scheduled
Split-adjusted performance
1W +23.9%1M +3.8%3M −1.4%6M −7.2%YTD +188.1%1Y −3.1%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 422 companies (100 = best)

6-month momentum67
Revenue growth—
Net margin—
Value (low P/E)—
Size44

Industry medians: 6-month return −25.5%, revenue growth +6.3%, net margin −39.7%, P/E 15.8×.

Short interest

Details →
Shares short6.1M−2.9% vs prior
Days to cover28.4Settled Sep 30
% of float13.7%
Short vol. 10d57.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HURATuHURA Biosciences$2.18+8.46%−7.2%———$138.9M
PYXSPyxis Oncology$1.68−1.75%−11.6%−100.0%——$140.1MCompare
RNAAtrium Therapeutics$8.20+0.49%−39.2%−21.9%−672.0%—$140.3MCompare
DERMJourney Medical$5.02−1.38%−2.5%+18.9%−1.7%—$141.7MCompare
CUECue Biopharma$18.66−1.22%+5.5%+166.7%−1943.2%—$135.6MCompare
MGNXMacroGenics$2.25−38.02%−29.5%+378.0%59.4%—$143.3MCompare
ANTXAN2 Therapeutics$3.55−2.47%−18.2%———$134.0MCompare
SPRBSpruce Biosciences$45.15−1.85%−17.0%———$129.8MCompare
UPBUpstream Bio$2.74−8.36%−70.5%−17.5%−5136.1%—$150.1MCompare

News about TuHURA Biosciences

All news →

No recent articles focused on TuHURA Biosciences.

Quick answers

What does TuHURA Biosciences do?
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
What is HURA's market cap?
$138.92M, based on the Oct 23 close of $2.18.
Does TuHURA Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HURA is sold short?
6.1M shares, 13.7% of float, as of Sep 30, 2026.
What sector is HURA in?
Healthcare, in the Pharmaceuticals industry.

About TuHURA Biosciences

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

HQ: Tampa, FL22 employeesListed Oct 18, 2024tuhurabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology